Bamboo Joint-Like Appearance of the Stomach: A Stable Endoscopic Landmark for Crohn's Disease Regardless of Anti-Tumor Necrosis Factor alpha Treatment

被引:0
|
作者
Hashiguchi, Keiichi [1 ]
Takeshima, Fuminao [1 ]
Akazawa, Yuko [1 ]
Matsushima, Kayoko [1 ]
Minami, Hitomi [1 ]
Yamaguchi, Naoyuki [1 ]
Shiozawa, Ken [1 ]
Ohnita, Ken [1 ]
Ichikawa, Tatsuki [1 ]
Isomoto, Hajime [1 ]
Nakao, Kazuhiko [1 ]
机构
[1] Nagasaki Univ, Grad Sch Biomed Sci, Dept Gastroenterol & Hepatol, Nagasaki 852, Japan
来源
MEDICAL SCIENCE MONITOR | 2014年 / 20卷
关键词
Crohn's Disease; Diagnosis; Endoscopy; Gastrointestinal; UPPER GASTROINTESTINAL-TRACT; INFLAMMATORY-BOWEL-DISEASE; GASTRIC BODY; INFLIXIMAB; CHILDREN; THERAPY; LESIONS; CARDIA; TRIAL;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: Bamboo joint-like appearance is a common yet easy-to-miss endoscopic finding in the stomach of patients with Crohn's disease (CD). Bamboo joint-like appearance (BJA) is characterized by swollen longitudinal folds transversed by erosive fissures or linear furrows. However, whether BJA is observed during the remission stage of CD and during the active stage is unclear. In particular, the relationship between the course of BJA and anti-tumor necrosis factor (TNF) alpha therapy has not been studied. We aimed to evaluate the course of BJA in CD patients treated with anti-TNF alpha therapy. Material/Methods: We examined 22 CD patients who underwent esophagogastroduodenal endoscopy before undergoing anti-TNF a treatment. We evaluated the changes in BJA, clinical activity using the CD activity index (CDAI), and endoscopic activity using the simple endoscopic score for CD (SES-CD) from 6 months to 1 year after anti-TNF alpha therapy. Results: Fifteen of 22 patients (68.1%) presented with BJA in the stomach, 13 of whom received follow-up esophagogastroduodenal endoscopy after anti-TNF alpha therapy. The mean CDAI and SES-CD scores significantly improved after anti-TNF alpha therapy (P<0.01). Despite the marked improvements in clinical and endoscopic findings, the BJA of the stomach remained unchanged in all the patients. Conclusions: The findings indicate that BJA is frequently observed in the stomach of CD patients, regardless of whether the patient has active disease or is in remission, even after anti-TNF alpha therapy. Thus, BJA may be a stable endoscopic landmark in CD.
引用
收藏
页码:1918 / 1924
页数:7
相关论文
共 50 条
  • [1] A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease
    Papamichael, Konstantinos
    Mantzaris, Gerassimos J.
    Peyrin-Biroulet, Laurent
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (04) : 493 - 501
  • [2] The Impact of Anti-Tumor Necrosis Factor Alpha Therapy on Postoperative Complications in Pediatric Crohn's Disease
    Dotlacil, Vojtech
    Bronsky, Jiri
    Hradsky, Ondrej
    Frybova, Barbora
    Coufal, Stepan
    Skaba, Richard
    Rygl, Michal
    EUROPEAN JOURNAL OF PEDIATRIC SURGERY, 2020, 30 (01) : 27 - 32
  • [3] Long-term clinical and endoscopic outcomes of ustekinumab in pediatric Crohn's disease with anti-tumor necrosis factor failure
    Yamamoto, Yoko
    Takeuchi, Ichiro
    Shimizu, Hirotaka
    Fujikawa, Hiroki
    Toda, Masanori
    Miyata, Eri
    To, Hiroaki
    Nagata, Satoru
    Arai, Katsuhiro
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2025, 40 (01) : 123 - 132
  • [4] Tacrolimus Salvage in Anti-Tumor Necrosis Factor Antibody Treatment-Refractory Crohn's Disease
    Gerich, Mark E.
    Pardi, Darrell S.
    Bruining, David H.
    Kammer, Patricia P.
    Becker, Brenda D.
    Tremaine, William T.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (06) : 1107 - 1111
  • [5] Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn's disease
    Zaccagna, A
    Bertone, A
    Puiatti, P
    Picciotto, F
    Sprujevnik, T
    Santucci, R
    Rossini, FP
    EUROPEAN JOURNAL OF DERMATOLOGY, 2003, 13 (03) : 258 - 260
  • [6] The Role of Oxidative Stress in Anti-tumor Necrosis Factor Antibody Treatment in Crohn's Disease
    Kupcova, V.
    Turecky, L.
    Uhlikova, E.
    CURRENT MEDICINAL CHEMISTRY, 2012, 19 (30) : 5226 - 5231
  • [7] The Effect of Anti-Tumor Necrosis Factor Alpha Agents on Postoperative Anastomotic Complications in Crohn's Disease: a Systematic Review
    El-Hussuna, Alaa
    Krag, Aleksander
    Olaison, Gunnar
    Bendtsen, Flemming
    Gluud, Lise L.
    DISEASES OF THE COLON & RECTUM, 2013, 56 (12) : 1423 - 1433
  • [8] Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease
    Netz, Uri
    Carter, Jane Victoria
    Eichenberger, Maurice Robert
    Dryden, Gerald Wayne
    Pan, Jianmin
    Rai, Shesh Nath
    Galandiuk, Susan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (27) : 4958 - 4967
  • [9] Long-term outcomes of endoscopic balloon dilation for intestinal strictures in patients with Crohn's disease during maintenance treatment with anti-tumor necrosis factor alpha antibodies
    Takeda, Teruyuki
    Kishi, Masahiro
    Takatsu, Noritaka
    Takada, Yasumichi
    Beppu, Tsuyoshi
    Miyaoka, Masaki
    Hisabe, Takashi
    Ueki, Toshiharu
    Arima, Hisatomi
    Hirai, Fumihito
    Yao, Kenshi
    DIGESTIVE ENDOSCOPY, 2022, 34 (03) : 517 - 525
  • [10] Anti-Tumor Necrosis Factor-Alpha (TNF-alpha) Treatment Strategies in Crohn's Disease
    Reimund, Jean-Marie
    Ratajczyk, Julia
    Sola, Brigitte
    Justum, Anne-Marie
    Muller, Christian D.
    RECENT PATENTS ON INFLAMMATION & ALLERGY DRUG DISCOVERY, 2007, 1 (01) : 21 - 34